We are live on ! Find out more
VTGN icon

VistaGen Therapeutics

33 hedge funds and large institutions have $1.82M invested in VistaGen Therapeutics in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 54 closing their positions.

New
Increased
Maintained
Reduced
Closed

11.76% more ownership

Funds ownership: 0.58%12.35% (+12%)

31% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 16

60% less funds holding

Funds holding: 8333 (-50)

62% less capital invested

Capital invested by funds: $4.79M → $1.82M (-$2.97M)

93% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 54

Holders
33
Holders Change
-50
Holders Change %
-60.24%
% of All Funds
0.52%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
11
Reduced
16
Closed
54
Calls
$31K
Puts
Net Calls
+$31K
Net Calls Change
+$31K

VTGN Hedge Fund Activity: Q2 2023 in Review

33 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2023, worth a combined $1.82M — down 62% from $4.79M a quarter earlier.

Sellers outnumbered buyers: 54 funds closed out of VTGN and 4 opened new positions — a net loss of 50 holders — while 16 trimmed existing stakes and 11 added.

The largest buyer was GSA Capital Partners, adding an estimated $548K. The largest seller was BlackRock, cutting an estimated $1.17M.

  • 33 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2023, down from 83 in Q1 2023.
  • Funds reported $1.82M of VistaGen Therapeutics stock for Q2 2023, down 62% quarter-over-quarter.
  • 4 funds opened new VistaGen Therapeutics positions in Q2 2023 and 54 closed out, a net change of -50 holders.
  • The largest VistaGen Therapeutics buyer in Q2 2023 was GSA Capital Partners, an estimated $548K added.
  • The largest VistaGen Therapeutics seller in Q2 2023 was BlackRock, an estimated $1.17M sold.

Based on aggregated 13F filings for Q2 2023.